Phosphatase and tensin homolog expression related to cetuximab effects in colorectal cancer patients: A meta-analysis
作者： Yue Shen
关键词:
摘要: AIM: To investigate the correlation between expression of phosphatase and tensin homolog (PTEN) cetuximab effects in colorectal cancer. METHODS: We searched PubMed, EMBASE ASCO to identify eligible studies. Finally, 8 randomized control studies were included meta-analysis. STATA 10.0 Software was used heterogeneity among individual summarize all Risk ratios (RRs) hazard (HRs) with 95% confidence intervals (CIs) assess strength association. RESULTS: Compared 20 266 patients loss PTEN, 206 496 intact PTEN protein had a better objective response rate cetuximab-based therapy (RR, 4.75; CI, 2.59-8.72; P < 0.001). positivity associated progression-free survival (PFS) (HR, 0.675; 0.473-0.964; = 0.031) but not overall (OS) 0.608; 0.411-0.899; 0.013). In KRAS wild-type status, did predict longer PFS or OS (PFS: HR, 0.707; 0.440-1.138; 0.154; OS: 0.943; 0.646-1.377; 0.761). CONCLUSION: Expression is related effect cancer should be considered treatment cetuximab.
sci-hub.st 参考文章(36)
Eric Van Cutsem, Claus-Henning Köhne, Erika Hitre, Jerzy Zaluski, Chung-Rong Chang Chien, Anatoly Makhson, Geert D'Haens, Tamás Pintér, Robert Lim, György Bodoky, Jae Kyung Roh, Gunnar Folprecht, Paul Ruff, Christopher Stroh, Sabine Tejpar, Michael Schlichting, Johannes Nippgen, Philippe Rougier, Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. The New England Journal of Medicine. ,vol. 360, pp. 1408- 1417 ,(2009) , 10.1056/NEJMOA0805019
Fotios Loupakis, Luca Pollina, Irene Stasi, Annamaria Ruzzo, Mario Scartozzi, Daniele Santini, Gianluca Masi, Francesco Graziano, Chiara Cremolini, Eliana Rulli, Emanuele Canestrari, Niccola Funel, Gaia Schiavon, Iacopo Petrini, Mauro Magnani, Giuseppe Tonini, Daniela Campani, Irene Floriani, Stefano Cascinu, Alfredo Falcone, PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 27, pp. 2622- 2629 ,(2009) , 10.1200/JCO.2008.20.2796
Claire E Saadeh, H Stephen Lee, Panitumumab: A Fully Human Monoclonal Antibody with Activity in Metastatic Colorectal Cancer Annals of Pharmacotherapy. ,vol. 41, pp. 606- 613 ,(2007) , 10.1345/APH.1H492
Andrea Sartore-Bianchi, Miriam Martini, Francesca Molinari, Silvio Veronese, Michele Nichelatti, Salvatore Artale, Federica Di Nicolantonio, Piercarlo Saletti, Sara De Dosso, Luca Mazzucchelli, Milo Frattini, Salvatore Siena, Alberto Bardelli, PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Research. ,vol. 69, pp. 1851- 1857 ,(2009) , 10.1158/0008-5472.CAN-08-2466
M Frattini, P Saletti, E Romagnani, V Martin, F Molinari, M Ghisletta, A Camponovo, L L Etienne, F Cavalli, L Mazzucchelli, PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. British Journal of Cancer. ,vol. 97, pp. 1139- 1145 ,(2007) , 10.1038/SJ.BJC.6604009
Rafael G. Amado, Michael Wolf, Marc Peeters, Eric Van Cutsem, Salvatore Siena, Daniel J. Freeman, Todd Juan, Robert Sikorski, Sid Suggs, Robert Radinsky, Scott D. Patterson, David D. Chang, Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer Journal of Clinical Oncology. ,vol. 26, pp. 1626- 1634 ,(2008) , 10.1200/JCO.2007.14.7116
Rebecca DerSimonian, Nan Laird, Meta-Analysis in Clinical Trials* Controlled Clinical Trials. ,vol. 7, pp. 177- 188 ,(1986) , 10.1016/0197-2456(86)90046-2
F. Perrone, A. Lampis, M. Orsenigo, M. Di Bartolomeo, A. Gevorgyan, M. Losa, M. Frattini, C. Riva, S. Andreola, E. Bajetta, L. Bertario, E. Leo, M.A. Pierotti, S. Pilotti, PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients Annals of Oncology. ,vol. 20, pp. 84- 90 ,(2008) , 10.1093/ANNONC/MDN541
Mauro Moroni, Silvio Veronese, Silvia Benvenuti, Giovanna Marrapese, Andrea Sartore-Bianchi, Federica Di Nicolantonio, Marcello Gambacorta, Salvatore Siena, Alberto Bardelli, Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study Lancet Oncology. ,vol. 6, pp. 279- 286 ,(2005) , 10.1016/S1470-2045(05)70102-9
Nicolas Moosmann, Ludwig Fischer von Weikersthal, Ursula Vehling-Kaiser, Martina Stauch, Holger G. Hass, Herrmann Dietzfelbinger, Daniel Oruzio, Stefan Klein, Klaus Zellmann, Thomas Decker, Mathias Schulze, Wolfgang Abenhardt, Gerhard Puchtler, Herbert Kappauf, Johann Mittermüller, Christopher Haberl, Andreas Schalhorn, Andreas Jung, Sebastian Stintzing, Volker Heinemann, Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group Journal of Clinical Oncology. ,vol. 29, pp. 1050- 1058 ,(2011) , 10.1200/JCO.2010.31.1936